Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Drug May Block Crohn’s Inflammation
Uncategorized

Drug May Block Crohn’s Inflammation

By medwebOct 1, 2003
Share
Facebook Twitter Email

October 7, 2003

Drug May Block Crohn’s Inflammation

CHICAGO— An investigational drug under study by Alan L. Buchman, MD, associate professor of medicine at Northwestern’s Feinberg School of Medicine, may block the intense abdominal pain, diarrhea, bleeding, and other symptoms of Crohn’s disease, a condition of unknown cause that affects up to 1 million Americans.

After receiving the experimental drug, called CNI-1493, Lynn Rogers, who has Crohn’s disease, experienced a complete remission of her disabling symptoms for more than eight months.

Rogers, 40, a third-grade teacher in Corpus Christi, Texas, who was one of the first people in the United States to receive the drug, was diagnosed with Crohn’s disease in 1997.

None of the standard treatments for Crohn’s disease Rogers received, including corticosteroids, imfliximab, and medications that suppress the immune system—which normally are used for transplant patients—were effective.

CNI-1493 is a mitogen-activated protein kinase inhibitor, a substance that prevents an enzyme from causing white blood cells to produce chemicals that cause inflammation.

Dr. Buchman is conducting a new study of CNI-1493, but only Crohn’s disease patients who have never received the drug are eligible to participate

Share. Facebook Twitter Email

Related Posts

Mar 29, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Comments are closed.

Latest News

Medical Education Day Celebrates Mentorship and Equity

Sep 29, 2023

Mapping Neural Activity Patterns and Odor Perception  

Sep 28, 2023

Lloyd-Jones Announces He is Stepping Down as Chair of Preventive Medicine

Sep 27, 2023

Small, Implantable Device Could Sense and Treat Cancer

Sep 26, 2023

Gene Linked to Glioblastoma Stem Cell Self-Renewal and Immunosuppression

Sep 26, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230914_NM461
20230914_NM644
20230914_NM345
20230914_NM444
20230914_NM464
20230914_NM520
20230914_NM673
20230914_NM641
20230914_NM612
20230914_NM608
20230914_NM602
20230914_NM597

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.